| Next 10 |
Ad
ATAI News and Press ATAI Life Sciences N.V.
News | ATAI Life Sciences N.V. (NASDAQ:ATAI)
-
2025-03-19 11:05:00 ET Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to study MDMA with a focus on troops on active duty. The money will be provided by the U.S. Department of Defense (DOD). Startups like atai Life Sciences N.V. (N...
-
2025-03-17 08:10:25 ET More on ATAI Life Sciences Atai: Following The Path That Spravato Laid And Moving Beyond It Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst atai Life Sciences prices $55M underwritten offering; shares down Ata...
-
2025-03-05 10:05:00 ET If you are considering using psychedelics in a non-clinical setting, you might want to hold off for a while. A recently published study has found that individuals who have bad psychedelic trips have a much higher risk of dying within 5 years. Entities like a...
-
2025-03-03 10:42:24 ET More on DAX Germany Index: Global Resilience: Why International Stocks Have Rallied Despite U.S. Trade Hostilities When Tariffs Hit: Stocks, Bonds, And Volatility European markets move higher, defense stocks lead Germany's manufacturing...
-
2025-02-27 12:45:14 ET Summary Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds. Standing on the shoulders of Johnson & Johnson's Spravato. Upcoming milestones and clinical trials. Psyche...
-
2025-02-25 15:13:26 ET More on Global X Funds - Global X DAX Germany ETF: SPX Option Volumes Hit Record High As Volatility Picks Up Germany DAX Technical: Bullish Acceleration Towards Fresh All-Time Highs Germany's next chancellor Merz calls for 'real independence' f...
-
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s manage...
-
2025-02-13 09:28:54 ET Read the full article on Seeking Alpha For further details see: atai Life Sciences prices $55M underwritten offering; shares down
-
2025-02-12 16:35:21 ET More on ATAI Life Sciences Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst atai Life Sciences falls on proposed public offering of common shares Atai CEO Rao optimistic about psychedelic therapies despite Lykos setbac...
-
2025-02-12 16:06:46 ET More on ATAI Life Sciences Atai Life Sciences: Positive BPL-003 Data In AUD Leads To Another Catalyst Atai CEO Rao optimistic about psychedelic therapies despite Lykos setback Atai reports positive data for psychedelic drug BPL-003 Seek...
Stock Information
Get ATAI Alerts
News, Short Squeeze, Breakout and More Instantly...
ATAI Life Sciences N.V. Company Name:
ATAI Stock Symbol:
NASDAQ Market:
-2.07% G/L:
$1.57 Last:
2,095,439 Volume:
$1.48 Open:
$1.57 Close:
ATAI Life Sciences N.V. Website:
Ad
-
2025-03-19 11:05:00 ET Walter Reed National Military Medical Center officials confirmed they are awaiting a $4.9m grant to study MDMA with a focus on troops on active duty. The money will be provided by the U.S. Department of Defense (DOD). Startups like atai Life Sciences N.V. (N...
-
2025-03-05 10:05:00 ET If you are considering using psychedelics in a non-clinical setting, you might want to hold off for a while. A recently published study has found that individuals who have bad psychedelic trips have a much higher risk of dying within 5 years. Entities like a...
-
NEW YORK and BERLIN, Feb. 24, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s manage...